Free Trial

Australia to buy extra 20 million doses of Pfizer vaccine

In this image made from video, Australian Prime Minister Scott Morrison speaks during a news conference in Canberra, Australia, Thursday, April 8, 2021. Australia on Thursday become the latest country to restrict use of the AstraZeneca vaccine by recommending that it not be given to people under age 50. (SBS via AP)

CANBERRA, Australia (AP) — Australia said Friday that it has finalized a deal to buy an extra 20 million doses of the Pfizer vaccine as it rapidly pivots away from its earlier plan to rely mainly on the AstraZeneca vaccine.

Prime Minister Scott Morrison announced the deal just hours after saying Australia would stop using the AstraZeneca vaccine for people aged under 50.

He said the deal means Australia will get a total of 40 million doses of the Pfizer vaccine by the end of the year, enough to inoculate 20 million people in the nation of 26 million.

Australia's pivot came after the European Medicines Agency said this week it had found a “possible link” between the AstraZeneca vaccine and rare blood clots, though regulators in the United Kingdom and the European Union emphasized that the benefits of receiving the vaccine continue to outweigh the risks for most people.

After the European agency's declaration, Australian drug regulators held a series of urgent meetings Thursday and recommended the Pfizer vaccine become the preferred vaccine for people under 50.

Morrison said there was no prohibition on the AstraZeneca vaccine and the risk of side effects was remote. He said the change was being made out of an abundance of caution.

The pivot represents a significant shift in Australia's overall approach and is likely to delay plans to have everybody inoculated by October.

A major part of Australia’s strategy had been the ability to make its own vaccines at home and not rely on shipments from abroad. It had planned to manufacture some 50 million doses of the AstraZeneca vaccine, enough for 25 million people. Australia had made no plans to make any other vaccines at home.

Even before the change, the government was facing criticism for a rollout program that's lagging behind those in most other developed nations. So far, Australia has administered just over 1 million vaccine doses.

Opposition Leader Anthony Albanese said the rollout was a debacle and Australians needed certainty about when they would be vaccinated.

“This government has failed. This government couldn’t run a choko vine up a back fence,” Albanese told reporters, referring to a plant that produces pear-shaped fruit and grows easily in the Australian climate.

Health Minister Greg Hunt said there would be some adjustments but everybody would be kept safe and would get vaccinated.

Australia has managed to stamp out community spread of the virus, allowing life to continue much as before the pandemic.

AstraZeneca noted Australia’s decision to restrict the vaccine's use was based on it having no community transmission.

“Overall, regulatory agencies have reaffirmed the vaccine offers a high-level of protection against all severities of COVID-19 and that these benefits continue to far outweigh the risks,” the company said in a statement.

Should You Invest $1,000 in Pfizer Right Now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRankâ„¢Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Pfizer (PFE)
4.8638 of 5 stars
$24.270.3%7.09%17.59Moderate Buy$29.17
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

Recent Videos

3 Defense Stocks Under $10 With Massive Upside
NVIDIA: Another 200% Growth Ahead? (PLUS 2 Companies Riding Along)
3 Rising Stocks You’ll Want on Your Watchlist

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines